- Home
- WIA vs CMPX Comparison
WIA vs CMPX Comparison
Compare WIA & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- CMPX
- Stock Information
- Founded
- WIA 2003
- CMPX 2014
- Country
- WIA United States
- CMPX United States
- Employees
- WIA N/A
- CMPX N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- WIA Finance
- CMPX Health Care
- Exchange
- WIA Nasdaq
- CMPX Nasdaq
- Market Cap
- WIA 186.8M
- CMPX 214.6M
- IPO Year
- WIA N/A
- CMPX N/A
- Fundamental
- Price
- WIA $8.09
- CMPX $2.61
- Analyst Decision
- WIA
- CMPX Strong Buy
- Analyst Count
- WIA 0
- CMPX 4
- Target Price
- WIA N/A
- CMPX $13.75
- AVG Volume (30 Days)
- WIA 39.2K
- CMPX 2.2M
- Earning Date
- WIA 01-01-0001
- CMPX 11-12-2024
- Dividend Yield
- WIA 12.29%
- CMPX N/A
- EPS Growth
- WIA N/A
- CMPX N/A
- EPS
- WIA N/A
- CMPX N/A
- Revenue
- WIA N/A
- CMPX $850,000.00
- Revenue This Year
- WIA N/A
- CMPX N/A
- Revenue Next Year
- WIA N/A
- CMPX $613.39
- P/E Ratio
- WIA N/A
- CMPX N/A
- Revenue Growth
- WIA N/A
- CMPX N/A
- 52 Week Low
- WIA $7.56
- CMPX $0.77
- 52 Week High
- WIA $8.91
- CMPX $2.73
- Technical
- Relative Strength Index (RSI)
- WIA 51.52
- CMPX 77.12
- Support Level
- WIA $7.94
- CMPX $2.34
- Resistance Level
- WIA $8.18
- CMPX $2.70
- Average True Range (ATR)
- WIA 0.08
- CMPX 0.29
- MACD
- WIA 0.02
- CMPX 0.12
- Stochastic Oscillator
- WIA 65.20
- CMPX 90.98
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.